Literature DB >> 3776912

A rapid, no-wash technic for immunophenotypic analysis by flow cytometry.

C W Caldwell, H M Taylor.   

Abstract

With the advent of fluorochrome-labeled monoclonal antibodies, it has now become possible to eliminate the removal of unbound antibodies during immunophenotypic analysis of lymphoid cells by flow cytometry. Suspensions of mononuclear cells from healthy controls and fluoresceinated monoclonal antibodies may be introduced directly into the flow cytometer. The percentage of nonwashed antibody-positive cells from healthy controls as compared with the conventional technic of cell washing shows a good correlation. However, the correlation is not as good when the lymphocytes from certain classes of diseased patients are analyzed. It appears that excessive washing in fact produces erroneous results for certain markers with cells from diseased patients. The no-wash technic is also applicable to various combinations of dual-fluorescence monoclonal antibody staining. This technic substantially reduces the processing time and, more importantly, eliminates some of the cell losses and artifacts induced during the process of cell washing. The shortened processing time has allowed rapid responsiveness in certain urgent clinical situations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3776912     DOI: 10.1093/ajcp/86.5.600

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  Surface activation markers of T lymphocytes: role in the detection of infection in neonates.

Authors:  S Hodge; G Hodge; R Flower; P Han
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

2.  A point mutation in a domain of gamma interferon receptor 1 provokes severe immunodeficiency.

Authors:  L M Allende; A López-Goyanes; E Paz-Artal; A Corell; M A García-Pérez; P Varela; A Scarpellini; S Negreira; E Palenque; A Arnaiz-Villena
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

3.  T lymphocyte anergy during acute infectious mononucleosis is restricted to the clonotypic receptor activation pathway.

Authors:  M Pérez-Blas; J R Regueiro; J R Ruiz-Contreras; A Arnaiz-Villena
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

4.  CD80/CD28 co-stimulation in human brucellosis.

Authors:  P Skendros; P Boura; F Kamaria; M Raptopoulou-Gigi
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

5.  Donor dependent, interferon-gamma induced HLA-DR expression on human neutrophils in vivo.

Authors:  W Reinisch; C Lichtenberger; G Steger; W Tillinger; O Scheiner; A Gangl; D Maurer; M Willheim
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

6.  Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection.

Authors:  M Timón; A Arnaiz-Villena; J Ruiz-Contreras; J T Ramos-Amador; A Pacheco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

7.  Selective involvement of monocytes by acquired myeloperoxidase deficiency in a case of chronic myelomonocytic leukemia.

Authors:  A De Pasquale; L Ginaldi; G Di Leonardo; S Francavilla; D Quaglino
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

8.  Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure.

Authors:  N M Al-Saady; E W Leatham; S Gupta; J T Kwan; J B Eastwood; C A Seymour
Journal:  Heart       Date:  1999-02       Impact factor: 5.994

9.  Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding.

Authors:  L M Allende; A Corell; J Manzanares; D Madruga; A Marcos; A Madroño; A López-Goyanes; M A García-Pérez; J M Moreno; M Rodrigo; F Sanz; A Arnaiz-Villena
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

10.  Memory and naive CD4+ lymphocytes in multiple sclerosis.

Authors:  A M Porrini; D Gambi; G Malatesta
Journal:  J Neurol       Date:  1992-10       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.